Female Infertility Diagnosis and Treatment Market 2022-2028

Description

List of Tables

Title:Global Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Ovulation Testing, Hysterosalpingography (HSG), Hysteroscopy, Imaging Testing, Ovarian Reserve Testing, Hormonal Level Testing, Genetic Testing, and Others)by Treatment (Drugs, Surgery, Intrauterine Insemination (IUI), Assisted Reproductive Technology (ART)) by End User(Hospitals and Clinics, Homecare, and Pathology and Diagnostic Centers) Forecast 2022-2028.

The global female infertility diagnosis and treatment market is anticipated to grow at a significant CAGR of 5.6% during the forecast period (2021-2028). Infertility affects millions of people of reproductive age across the globe and has an impact on their families and communities. Infertility may cause in females or males. In males, infertility is most commonly caused by problems in the ejection of semen, absence or low levels of sperm, or abnormal shape. In female infertility may be caused by a range of abnormalities of the ovaries, uterus, fallopian tubes, and the endocrine system, and among others. A survey of 692 female surgeons published in JAMA Surgery in July 2021 found that 42% had suffered a pregnancy loss, more than double the rate of the overall population.

Moreover, a lack of trained personnel and the necessary equipment and infrastructure, and the currently high costs of treatment medicines, are major barriers even for countries that are actively addressing the needs of people with infertility, which in turn hinders the growth of the market.

The global female infertility diagnosis and treatment market is segmented on the basis of diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into the ovulation testing, ovarian reserve testing, hormonal level testing, hysterosalpingography (HSG), hysteroscopy, imaging testing, genetic testing, and others. Based on diagnosis, the hysterosalpingography (HSG) segment hold's a leading market share in coming years. The increasing prevalence of genetic disorders such as Down syndrome, ONTD, and other disorders are the prominent factor that drives the market growth. Moreover, the growing laboratory application of non-invasive, hysterosalpingography (HSG) is also considered a major factor that boosts the segments during the forecast period.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The European region is anticipated to grow at the fastest rate, owing to the well sounded healthcare systems, and the region have the highest rate of diagnosis and treatment adoption among all other countries, resulting in a key region for the global female infertility diagnosis market.

The major companies serving the global female infertility diagnosis and treatment market are: Bayer AG, Church & Dwight Co. Inc., Genea Ltd., Pfizer Inc., Vitrolife Sweden AB , Esco Group, Fairhaven Health, Ferring B.V., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies contribute to drug targets and set high-quality technology platforms to jointly develop innovative treatment options.

Research Methodology

The market study of the global female infertility diagnosis and treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Female Infertility Diagnosis And Treatment Market Research And Analysis By Diagnosis
Global Female Infertility Diagnosis And Treatment Market Research And Analysis By Treatment
Global Female Infertility Diagnosis And Treatment Market Research and Analysis by End User

The Report Covers:

Comprehensive research methodology of the global female infertility diagnosis and treatment market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global female infertility diagnosis and treatment market.
Insights about market determinants that are stimulating the global female infertility diagnosis and treatment market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026621

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Female Infertility Diagnosis and Treatment Market
Recovery Scenario of Global Female Infertility Diagnosis and Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight and Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key CompanyAnalysis
- 3.1.1. Bayer AG
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Church & Dwight Co. Inc
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Genea Ltd.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. Pfizer Inc
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Vitrolife Sweden AB
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Female Infertility Diagnosis and Treatment Market by Diagnosis
- 4.1.1. Ovulation Testing
- 4.1.2. Hysterosalpingography (HSG)
- 4.1.3. Hysteroscopy
- 4.1.4. Imaging Testing
- 4.1.5. Ovarian Reserve Testing
- 4.1.6. Hormonal Level Testing
- 4.1.7. Genetic Testing
- 4.1.8. Others (Laparoscopy)
4.2. Global Female Infertility Diagnosis and Treatment Market by Treatment
- 4.2.1. Drugs
- 4.2.2. Surgery
- 4.2.3. Intrauterine Insemination (IUI)
- 4.2.4. Assisted Reproductive Technology (ART)
4.3. Global Female Infertility Diagnosis and Treatment Market by End-User
- 4.3.1. Hospitals and Clinics
- 4.3.2. Homecare
- 4.3.3. Pathology and Diagnostic Centers

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Cook Group Inc.
6.2. Eli Lilly & Co.
6.3. Esco Group
6.4. Fairhaven Health
6.5. Ferring B.V.
6.6. Fujifilm Irvine Scientific, Inc.
6.7. GlaxoSmithKline Plc.
6.8. Merck KGaA
6.9. Princeton BioMeditech Corp.
6.10. Tempest Therapeutics, Inc.